Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Indiva Reports Fiscal Year 2023 Results Including Record Positive EBITDA and Income (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Galecto Inc GLTO

Healthcare Biotechnology
Galecto, Inc. is a clinical-stage biotechnology company. The Company is focused on developing novel small molecule therapeutics that are designed to target the biological processes that lie at the heart of cancer and fibrotic diseases. The Company’s initial focus is on the development of small molecule inhibitors of galectin-3 and lysyl oxidase-like 2 (LOXL2). It is developing GB0139 for the... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:GLTO)

Topline Results from MYLOX-1 Trial Demonstrate Reduction in Fibrosis of the Bone Marrow in Patients with Myelofibrosis

GlobeNewswire December 21, 2023

Galecto Presents Updated Clinical Data at ESMO Congress 2023 and Provides Update on Phase 1b/2a GALLANT-1 Trial

GlobeNewswire October 23, 2023

Galecto Announces Plans to Explore Strategic Alternatives

GlobeNewswire September 26, 2023

Galecto to Present at Investor Conferences in September

GlobeNewswire August 31, 2023

Galecto Announces Topline Results from Phase 2b GALACTIC-1 Trial of GB0139 for the Treatment of Idiopathic Pulmonary Fibrosis

GlobeNewswire August 15, 2023

Galecto Reports Second Quarter Operating and Financial Results

GlobeNewswire July 31, 2023

Galecto Set to Join Russell Microcap® Index

GlobeNewswire June 20, 2023

Galecto to Present at the Upcoming Jefferies Healthcare Conference

GlobeNewswire May 30, 2023

Galecto Completes Dosing in 52-Week Phase 2b GALACTIC-1 Trial of GB0139 in Idiopathic Pulmonary Fibrosis

GlobeNewswire May 23, 2023
View More News ››

Opinion & Analysis (NDAQ:GLTO)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:GLTO)

Galecto ($GLTO) Phase 2a Trial Shows Reduction in Fibrosis

<< View Post To Watch Video >>         
GreenStockNews - September 29, 2022
View more Bullboard ››

Vertiqal Studios Corp.

Vertiqal Studios Corp.

Vertiqal Studios is a leading global digital media entertainment, production, and distribution company redefining the ...
View More »